A medication long trusted to ease the burden of failing hearts may now offer something to those struggling with a different kind of weight. Spironolactone, a diuretic in use since the late 1950s, has shown in both animal studies and Veterans Affairs patient records that it may meaningfully reduce alcohol cravings and consumption — particularly among the heaviest drinkers. The finding arrives at a moment when only two medications are considered reliably effective for a condition that quietly affects 14.5 million Americans, most of whom never receive any treatment at all. Science, it seems, some
Gizmodo Australia
· Sep 20, 2022
· health
· 3 min de leitura
High
Apuração: Verificado
Heart Drug Shows Promise in Treating Alcohol Use Disorder
Approximately 14.5 million Americans struggle with alcohol use disorder, with less than 10% receiving treatment annually.
◉
Health & Medicine
8412 artigos relacionados
Retatrutide: Eli Lilly's Triple-Action Weight-Loss Drug Poised to Resh…
The Economic Times · 100% correspondência
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight-Loss Treatment
Interesting Engineering · 99% correspondência
Eli Lilly's Oral GLP-1 Pill Shows Promise for Diabetes and Weight Loss
TODAY · 99% correspondência
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight Loss Drug
ScienceAlert · 99% correspondência
Moderna's personalized mRNA melanoma vaccine shows promise in preventi…
CBS News · 99% correspondência
Cobertura Relacionada
BBC News · Aug 25
School asbestos exposure linked to woman's death at 46, family claims
A woman died from mesothelioma at 46, likely exposed to asbestos at her Cardiff school decades earlier. Her family is su…
Future of Personal Health - · Aug 25 NGS Technology Transforms Uncertain Infections Into Actionable DiagnosesHybrid-capture NGS technology helps clinicians identify pathogens in diagnostically challenging cases by simultaneously …
The Guardian · Aug 25 Shark attack survivor Leah Stewart recalls 'monster' in first interview since losing armLeah Stewart, who lost her arm in a June shark attack at Coogee Beach, recalls the traumatic encounter in her first inte…
Education News Canada · Aug 25 Systemic racism, restrictive policies block Black Canadians from blood donationBlack Canadians face systemic barriers to blood donation despite critical need for ethnicity-matched blood for sickle ce…
Viés e Enquadramento
⚖
Article presents promising research on spironolactone for alcohol use disorder with straightforward reporting, minimal loaded language, though lacks critical perspective on study limitations and competing treatments.
Bias Direction
center
Confidence
MED
Optimistic framing of medical breakthrough using 'second act' metaphor and progressive disclosure of drug's expanding applications, positioning spironolactone as a potential solution to an undertreated condition.
second act
could see a second act
struggling with
few treatments
promising research
Limitations of animal-to-human translation in drug research
Efficacy comparison with existing alcohol use disorder treatments
Potential side effects or contraindications not mentioned
Expert skepticism or cautionary viewpoints from addiction specialists
Cost and accessibility considerations
Long-term efficacy data or duration of treatment effects
Perspectives from people with lived experience of alcohol use disorder
Impacto Geopolítico
🌎
Medical research on repurposing spironolactone for alcohol use disorder has no direct geopolitical implications; this is a domestic health policy matter.
Escalation Risk
low
Confidence
HIGH
Lente Econômica
📈
Government research suggests spironolactone, an existing heart medication, may reduce alcohol cravings and consumption, potentially creating a new therapeutic market and reducing healthcare costs from alcohol use disorder.
Market Signal
bullish
Confidence
MED
Pharmaceutical and biotechnology
Healthcare and medical services
Mental health and addiction treatment
Hospital and clinical services
Patients with alcohol use disorder could access a lower-cost treatment option using an existing, affordable generic medication. This may reduce treatment barriers and improve health outcomes for millions struggling with addiction, potentially decreasing out-of-pocket costs.
FDA may expedite approval pathways for repurposed drugs. Healthcare systems may expand spironolactone prescribing for off-label use. Insurance coverage policies may evolve to include this indication. Public health agencies may increase funding for addiction treatment research and implementation.